Meeting
2022 ASCO Genitourinary Cancers Symposium
Nemvaleukin alfa in patients with advanced renal cell carcinoma: ARTISTRY-1.
Authors
Emiliano Calvo
START Madrid-CIOCC, Centro Integral Oncológico Clara Campal, Hospital Madrid Norte Sanchinarro, Madrid, Spain
Emiliano Calvo , Valentina Boni , Arvind Chaudhry , Philip R. Debruyne , Seth D Rosen , Yan Wang , Lei Sun , Monali Desai, MD , Rita P. Dalal , Yangchun Du , Julie R. Graham , Piotr Tomczak, MD
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Renal Cell Cancer; Adrenal, Penile, Urethral, and Testicular Cancers
Track
Renal Cell Cancer,Adrenal Cancer,Penile Cancer,Testicular Cancer,Urethral Cancer
Sub Track
Therapeutics
Clinical Trial Registration Number
NCT02799095
Citation
J Clin Oncol 40, 2022 (suppl 6; abstr 330)
DOI
10.1200/JCO.2022.40.6_suppl.330
Abstract #
330
Poster Bd #
L8
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
ARTISTRY-1: Nemvaleukin alfa monotherapy and in combination with pembrolizumab in patients (pts) with advanced solid tumors.
First Author: Valentina Boni
Poster
2019 ASCO Annual Meeting
Intravenous administration of ALKS 4230 as monotherapy and in combination with pembrolizumab in a phase I study of patients with advanced solid tumors.
First Author: Ulka N. Vaishampayan
Poster
2022 ASCO Annual Meeting
ARTISTRY-3: Effect of nemvaleukin alfa with a less frequent IV dosing schedule as monotherapy and in combination with pembrolizumab and impact on the tumor microenvironment (TME) in patients (pts) with advanced solid tumors.
First Author: Sarina Anne Piha-Paul
Poster
2022 ASCO Gastrointestinal Cancers Symposium
Nemvaleukin alfa combination therapy for gastrointestinal (GI) cancers: Preclinical evidence and clinical data from the ARTISTRY-1 trial.
First Author: Ulka N. Vaishampayan